Developmental Cell, Volume 56

Supplemental information

The ESCRT machinery counteracts

Nesprin-2G-mediated mechanical

forces during nuclear envelope repair

Samuel S. Wallis, Leandro N. Ventimiglia, Evita Otigbah, Elvira Infante, Miguel Angel Cuesta-Geijo, Gururaj Rao Kidiyoor, M. Alejandra Carbajal, Roland A. Fleck, Marco Foiani, Sergi Garcia-Manyes, Juan Martin-Serrano, and Monica Agromayor



Figure S1: BROX requires farnesylation for NE localisation and does not recruit CHMP4B to NE rupture sites. Related to Figure 1.

(A) Trace analysis of representative individual ruptures of similar size from siCTRL and siBROX treated cells and included in Figure1A.

(**B-C**) Analysis of BROX localisation in live HT1080 cells expressing mCherry-Emerin and GFP-L-BROX^r wild-type (WT) or non-farnesylated mutant (C408S) (B) Deconvolved images corresponding to the quantifications shown in (C). White lines mark the region of the NE where the fluorescence intensity profile was quantified. Scale bar, 10μm. (C) Fluorescence intensity profiles of HT1080 GFP-L-BROX^r WT (top) or C408S (bottom) cells.

(D-E) Time-lapse analysis of HT1080 cells expressing mCherry-NLS and GFP-L-BROX^r WT or C408S migrating through 4 μ m constrictions after treatment with siBROX. Hoechst was added to stain DNA. (D) Representative images of the quantifications shown in (E). Scale bar, 10 μ m. (E) Percentage of BROX-decorated NERDIS. GFP-L-BROX^r WT n=80; GFP-L-BROX^r C408S n=81; p<0.0001. Cell lysates were examined by blotting with the indicated antibodies.

(F) Recovery kinetics of NE integrity after NERDI in HT1080 wild-type (WT; n=29) or BROX-depleted (δBROX; n=46) cells stably expressing mCherry-NLS. Cell lysates were examined by blotting with the indicated antibodies.

(G-H) Analysis of DNA damage in HT1080 wild-type (WT) and BROX-depleted clone2 (δ BROX C2) cells stained with α -53BP1 or α - γ H2AX antibodies and Hoechst. (G) Quantification of 53BP1 and γ H2AX -positive foci. The samples used for HT1080 WT were the same as in Figure 1I. WT n=147; HT1080^{δ BROX}C2 n=147; p<0.0001. Median and quartiles are shown in red and blue respectively and cell lysates were examined by blotting with the indicated antibodies. (H) Representative images of the quantifications shown in (G). Arrowheads show DNA damage foci. Scale bar, 15µm.

(I-J) Time-lapse analysis of HT1080 cells expressing mCherry-NLS and CHMP4B-L-GFP. Cells were transfected with indicated siRNAs and imaged while migrating through 4 μ m constrictions. Hoechst was added to stain DNA. (I) Percentage of CHMP4B-decorated NERDI. siCTRL n=238; siCHMP7 n=81; siBROX n=137; ****p<0.0001, ^{N.S}p>0.05. Cell lysates were analysed by blotting with the indicated antibodies. (J) Representative images of the quantification shown in (I). Scale bar, 10 μ m.

Figure S2



Figure S2: NE phenotypes resulting from BROX depletion can be rescued by re-expression of GFP-L-BROX^r. Related to Figure 2.

(A-D) Analysis of actin cables in HT1080 wild-type (WT) or BROX-depleted (δ BROX) stably expressing GFP-Lap2 β and stained with SiR-actin. (A) Percentage of cells with nuclear actin cables. WT: n=160; δ BROX n=116; p=0.0186. (B) Representative images of the quantifications shown in (A). Arrowhead denotes an actin cable. Scale bar, 5 μ m. (C-D) Percentage of cells with nuclear actin cables in cells treated with Y27632 or blebbistatin. siCTRL+H₂O: n=675; siBROX+H₂O n=611; siCTRL+Y27632: n=577; siBROX+Y27632 n=576; siCTRL+DMSO: n=680; siBROX+DMSO n=670; siCTRL+Blebb: n=570; siBROX+Blebb n=656; *p=0.0464, **p= 0.0068, ****p<0.0001

(E-F) Analysis of nuclear morphology in HT1080 cells stably expressing either GFP (GFP- \emptyset) or GFP-L-BROX^r after treatment with the indicated siRNAs and staining with α -Lamin B1 antibody. (E) Quantification of percentage of cells with NE invaginations. Non-transfected n=559; GFP- \emptyset +siCTRL n=487; GFP- \emptyset +siBROX n=523; GFP-L-BROX^r+siCTRL n=667; GFP-L-BROX^r+siBROX n=721; **p=0.0031, ***p=0.0007, ^{N.S}p>0.05. Cell lysates were analysed by blotting with the indicated antibodies. (F) Representative images of quantifications shown in (E). Arrowheads indicate NE invaginations. Scale bars, 10µm.

(G-H) Analysis of nuclear morphology in HT1080 WT and BROX-depleted cells (δ BROX C1 and δ BROX C2) stably expressing either GFP-ø or GFP-L-BROX^r after staining with α -Lamin B1 antibody. (G) Quantification of percentage of cells with NE invaginations. WT+GFP-ø n=246; δ BROX C1+GFP-ø n=283; δ BROX C1+GFP-L-BROX^r n=199, δ BROX C2+GFP-ø n=291; δ BROX C2+GFP-L-BROX^r n=270; ****p<0.001, ***p<0.001, ^{N.S}p>0.05. Cell lysates were analysed by blotting with the indicated antibodies. (H) Representative images of quantifications shown in (G). Arrowheads indicate nuclear NE invaginations. Scale bar, 10µm.

(I) Typical force-extension curves conducted on a live cell when only the plasma membrane (PM; top) or also the nuclear membrane (NM; bottom) are indented. Rupture of the plasma membrane (top inset) is hallmarked by two consecutive discontinuities in the contact region of the force-extension trace, while NE rupture can be fingerprinted by the presence of up to six discontinuities, corresponding to the rupture of the plasma membrane (two) in addition to the four nuclear membranes (bottom inset).

(J-K) Scatterplot of the breakthrough force versus the cell height in the PM or the NM. Histograms display the distribution of breakthrough forces corresponding to the rupture of the PM (J) or the NM (K). The colour-code corresponds to the type of cell analysed: WT (black), δ BROX (green) and δ LMNA (red). Number of traces are the same as in Figure 2I.



D









L

J











oBROX siNesprin-2

SiR-Actin GFP-Emerin





δBROX siCTRL δBROX siNesprin-2

Figure S3: Characterisation of BROX interactions and dependence on Nesprin-2G interaction for localisation during NERDI. Related to Figure 3.

(A) BROX was tested for interactions with CHMP4B (left graph), CHMP5¹⁴⁹⁻²¹⁹ (middle graph) or Nesprin-2G^{SR29-33} (right graph) by yeast two-hybrid assays.

(B) Diagram schematic of human mini-Nesprin-2G (hmN2G) constructs used. hmN2G is based on the previously published mN2G but uses the human sequence of Nesprin-2G. hmN2GSR²⁹⁻³³ contains the BROX interacting region identified in the yeast-two hybrid screen flanked by flexible linkers.

(C-D) Time-lapse analysis of HT1080 cells expressing mCherry-NLS and GFP-L-BROX^r wild-type (WT) or L350A mutant cells migrating through 4µm constrictions. Hoechst was added to stain DNA. (C) Representative images of quantifications shown in (D). Scale bar, 10µm. (D) Percentage of BROX-decorated NERDI. GFP-L-BROX^r WT n=80; GFP-L-BROX^r L350A n=113; *p=0.0058. The dataset corresponding to GFP-L-BROX^r WT is the same used in the quantification shown in Figure S1E. Cell lysates were examined by blotting with the indicated antibodies.

(E) Quantification of the rupture recovery times in HT1080 cells expressing mCherry-NLS and GFP-L-BROX^r wild-type (WT) or mutant forms (H204A, L350A, C408S); ***P=0.0007, **P=0.0067, *P=0.0391.

(F-G) Analysis of nuclear morphology in HT1080 wild-type (WT) or BROX-depleted (δ BROX) cells transfected with indicated siRNAs and stained with α -Lamin B1 antibody. (F) Percentage of cells with NE invaginations. WT+siCTRL n=245; WT+siNesprin-2 n=168; δ BROX+siCTRL n=176; δ BROX+siNesprin-2 n=193; ****P<0.0001, ***P<0.001. Cell lysates were analysed by blotting with the indicated antibodies. (G) Representative images of quantifications shown in (F). Arrowheads indicate NE invaginations. Scale bar, 20µm.

(H) HT1080 cells transfected with either control or Nesprin-2-specific siRNA were analysed for Nesprin-2 mRNA levels by qPCR. Results were normalised to GAPDH mRNA levels.

(I) Representative images of quantifications in Figure 3H. Arrowheads indicate INTs. Scale bar, 10μm.
(J) Representative images of quantifications in Figure 3I. Arrowhead indicates an actin cable. Scale bar, 10μm.







С





I









Figure S4: BROX-CHMP5 interaction is not required for BROX recruitment to rupture sites and GFP-SOUBA perinuclear rings form in cells that will undergo NERDI. Related to Figure 4.

(A) GFP pull-down experiments of 293T transiently co-expressing HA-Ubiquitin together with GFP- $hmN2G^{SR29-33}$ or GFP-hmN2G. Eluted fractions were examined by Western blot using the indicated antibodies and the ratio between HA and GFP bands intensity in the eluted fractions was plotted. p=0.0036

(B-C) Time-lapse analysis of HT1080 cells expressing mCherry-NLS and GFP-L-BROX^{r.} wild-type (WT) or mutant (H204). Hoechst was added to stain DNA. (B) Representative images of the quantifications shown in (C). Scale bar, 5 μ m. Arrowheads highlight site of rupture (C) Percentage of BROX-decorated NERDI. WT n=38; H204A n=59 cells; p=0.0244. The movies used to quantify recruitment for WT conditions were the same as the ones used for the recruitment quantification shown in Figure 3D. Cell lysates were examined by blotting with the indicated antibodies.

(**D**) FACS analysis of HT1080 cells stably expressing GFP-empty (GFP- \emptyset) or GFP-hmN2G^{SR29-33} after transfection with indicated siRNAs. Left: GFP fluorescence intensity profiles corresponding to one representative experiment. Right: quantification of GFP mean fluorescence intensity (MFI). *p<0.05, ^{N.S}p>0.05.

(E) Quantitation of the number of INTs decorated with Nesprin-2G per cell in HT1080 and HT1080^{δ BROX} cells stably expressing GFP-hmN2G^{SR29-33}. WT n=16; δ BROX n=10; p<0.0001.

(F) Analysis of GFP-SOUBA expression in HT1080 cells stably expressing GFP-ø or GFP-SOUBA. Cell lysates were analysed by blotting with indicated antibodies.

(G-J) Live imaging of HT1080 cells co-expressing GFP-SOUBA and mCherry-NLS. (G) Analysis of GFP-SOUBA localisation in cells transfected with the indicated siRNAs. Scale bars, 10 μ m. (H) percentage of cells with perinuclear GFP-SOUBA accumulation. siCTRL n=588; siNesprin2 n=437; siUFD1 n=504; siNesprin2+siUFD1 n=468; **p=0.025, ^{N.S}p>0.05. (I) Analysis of GFP-SOUBA perinuclear accumulation in cells undergoing NERDI. SOUBA-negative n=1857; SOUBA-positive n=88; p<0.0001. (J) Percentage of cells showing NERDI after transfection with indicated siRNA. siCTRL n=2016; siUFD1 n=1910, p=0.9309.